Aptose Biosciences (APTO) Rating Lowered to Hold at Zacks Investment Research

Share on StockTwits

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

Other research analysts have also issued research reports about the stock. HC Wainwright set a $9.00 price objective on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Monday, November 26th. B. Riley assumed coverage on Aptose Biosciences in a research note on Friday, November 16th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a research note on Wednesday, December 12th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $5.63.

Shares of Aptose Biosciences stock traded down $0.02 during trading on Tuesday, hitting $2.25. 556 shares of the company were exchanged, compared to its average volume of 260,007. Aptose Biosciences has a fifty-two week low of $1.78 and a fifty-two week high of $4.55. The company has a market capitalization of $83.48 million, a P/E ratio of -4.29 and a beta of 1.84.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. As a group, equities research analysts expect that Aptose Biosciences will post -0.87 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Aptose Biosciences stock. Citadel Advisors LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 48,239 shares of the biotechnology company’s stock, valued at approximately $125,000. Citadel Advisors LLC owned 0.13% of Aptose Biosciences as of its most recent SEC filing. 3.28% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Article: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ASV  Rating Increased to Hold at Zacks Investment Research
ASV Rating Increased to Hold at Zacks Investment Research
Aptose Biosciences  Rating Lowered to Hold at Zacks Investment Research
Aptose Biosciences Rating Lowered to Hold at Zacks Investment Research
Analysts Anticipate Riverview Bancorp, Inc.  to Announce $0.18 Earnings Per Share
Analysts Anticipate Riverview Bancorp, Inc. to Announce $0.18 Earnings Per Share
Spire Healthcare Group PLC  Given Consensus Recommendation of “Hold” by Analysts
Spire Healthcare Group PLC Given Consensus Recommendation of “Hold” by Analysts
Zacks Investment Research Downgrades bluebird bio  to Sell
Zacks Investment Research Downgrades bluebird bio to Sell
China Biologic Products  Lifted to “Hold” at Zacks Investment Research
China Biologic Products Lifted to “Hold” at Zacks Investment Research


Leave a Reply

© 2006-2019 Ticker Report